Recent developments highlight Glaukos' efforts to strengthen its retinal pipeline through a licensing deal and continued market commentary on its stock performance and sector positioning.

• Glaukos strengthened its retinal pipeline through a licensing deal with RevOpsis, enhancing its therapeutic portfolio in retinal disease [N7].
• The company reported a 58% increase in net sales for Q3 2026 compared to Q3 2025, driven by higher sales volume and pricing of iDose TR and growth in corneal health products [S2].
• Gross margin improved to 85% in Q3 2026 from 78% in Q3 2025, reflecting operational efficiencies and product mix [S2].
• Selling, general and administrative expenses increased by 58% in Q3 2026, including a $14.1 million accrual related to a Resolution Agreement and investments in commercial infrastructure [S2].
• Research and development expenses rose 26% in Q3 2026, reflecting increased clinical development activities and compensation costs [S2].
• Net income for Q3 2026 was $2.0 million, reversing a net loss of $16.2 million in the prior year quarter [S2].
• Liquidity remains strong with $162.3 million in cash and equivalents and a current ratio of 4.57 as of September 30, 2026 [sec_financial_snapshot].

The company has demonstrated strong revenue growth driven by increased adoption of its iDose TR and corneal health products. Expansion in international markets and new product launches, including pipeline advancements in retinal therapies, provide avenues for continued commercial momentum. Operational improvements have led to higher gross margins and a return to net profitability in recent quarters. Strategic licensing deals and investments in R&D support innovation and potential market expansion.

GLAUKOS faces risks from reimbursement challenges in certain international markets and potential supply chain or manufacturing inefficiencies that could impact gross margins. Increased operating expenses, including significant accruals and investments in commercial infrastructure, may pressure profitability. The company operates in a competitive medical device and pharmaceutical landscape with regulatory and clinical development uncertainties. Currency fluctuations and reliance on third-party manufacturers for some products add operational complexity.

GLAUKOS benefits from proprietary technologies in ophthalmology, including patented implantable devices and drug delivery systems. Its integrated manufacturing capabilities and direct sales infrastructure in key markets support competitive positioning. The company's licensing agreements and ongoing R&D pipeline contribute to product differentiation and potential future growth avenues. Regulatory approvals, such as FDA clearance for repeat treatments, enhance market access and product lifecycle management.

• Regulatory and Clinical Development Risks: The company’s product candidates require regulatory approvals which involve uncertain timelines and outcomes. Clinical trial results and regulatory decisions can impact product commercialization.
• Reimbursement and Pricing Pressure: Challenges in obtaining favorable reimbursement, especially internationally, may affect sales growth and margins.
• Manufacturing and Supply Chain Risks: Dependence on internal and third-party manufacturing facilities exposes the company to risks of production disruptions, quality control issues, and cost fluctuations.
• Operational Expense Growth: Rising SG&A and R&D expenses, including accruals and stock-based compensation, may pressure operating margins if revenue growth does not keep pace.
• Currency Exchange Rate Exposure: Foreign currency fluctuations impact reported results, particularly for international sales and intercompany transactions.

• GLAUKOS Corp operates primarily in ophthalmology, focusing on development and commercialization of therapies across glaucoma, corneal health, and retinal disease end markets [S2].
• The company generates net sales mainly from its iDose TR, iStent family of products, Epioxa, and other drug formulations, along with proprietary bioactivation systems [S2].
• Customers include ambulatory surgery centers, hospitals, specialty pharmacies, physician private practices, and independent distributors internationally [S2].
• GLAUKOS sells most products through a direct sales organization in the U.S. and through direct subsidiaries or independent distributors internationally [S2].
• Manufacturing occurs at company facilities in San Clemente, California (iStent and iDose TR) and Burlington, Massachusetts (bioactivation systems), with third-party manufacturers in the U.S. and Germany producing Epioxa and related drugs [S2].
• Net sales increased by approximately 58% for Q3 2026 compared to Q3 2025, driven by higher volume and pricing of iDose TR and growth in corneal health products, notably Epioxa [S2].
• Gross margin improved to 85% in Q3 2026 from 78% in Q3 2025, reflecting product mix and operational efficiencies [S2].
• Selling, general and administrative expenses increased by 58% in Q3 2026 compared to Q3 2025, driven by personnel costs, stock-based compensation, customer support, commercial infrastructure growth, and a $14.1 million accrual related to a Resolution Agreement [S2].
• Research and development expenses rose 26% in Q3 2026 versus Q3 2025, reflecting increased compensation and clinical development activities across glaucoma, corneal, and retinal programs [S2].
• Net income for Q3 2026 was $2.0 million compared to a net loss of $16.2 million in Q3 2025 [S2].
• Liquidity as of September 30, 2026 included $162.3 million in cash and equivalents, current assets of $579.7 million, current liabilities of $126.7 million, with a current ratio of 4.57 and cash ratio of 1.28 [sec_financial_snapshot].
• The company has ongoing research and development programs including next-generation iDose and Epioxa products and earlier-stage glaucoma, corneal, and retinal therapeutic candidates [S2].
• Recent news highlights include a licensing deal to strengthen the retinal pipeline through RevOpsis, and multiple analyst and market commentaries on Glaukos stock performance and sector positioning [N7][N1][N2].